Enobosarm (VERU-024)
Preservation of lean muscle mass & augmentation of fat loss in overweight/obese patients on GLP-1 RA therapy
Phase 2bActive
Key Facts
Indication
Preservation of lean muscle mass & augmentation of fat loss in overweight/obese patients on GLP-1 RA therapy
Phase
Phase 2b
Status
Active
Company
About Veru
Veru Inc. is a NASDAQ-lated biopharmaceutical company (VERU) with a focused mission to develop novel oral therapeutics for cardiometabolic and inflammatory diseases. Its core strategy leverages two late-stage assets: enobosarm, a SARM designed to combat muscle loss associated with GLP-1 weight loss drugs, and sabizabulin, an oral microtubule disruptor being repurposed as a broad anti-inflammatory for atherosclerosis. The company has reported positive Phase 2b topline results for enobosarm and is advancing both programs into further clinical trials, positioning itself at the intersection of two of healthcare's largest markets.
View full company profile